



Claims:

1.(Cancelled) A compound selected from the group consisting of



and




5 wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-OCONH_2$; and

R_4 is hydroxy or carbonyl.

10 2. (Cancelled) The compound of claim 1 having the general structure:



wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;


R₃ is hydroxy or -OCONH₂; and
R₄ is hydroxy or carbonyl.

3. (Cancelled) The compound of claim 2 wherein R₇ and R₈ are H;

5 R₁ is H or F; and

R₄ is hydroxy or carbonyl.

4. (Cancelled) The compound of claim 1 having the general structure:



10 wherein R₁ is selected from the group consisting of halo, haloalkyl and hydroxy;
R₇ and R₈ are independently selected from the group consisting of H, halo,
alkyl, haloalkyl and hydroxy; and


R₃ is hydroxy or -OCONH₂.

15 5. (Cancelled) The compound of claim 4 wherein R₇ and R₈ are H;

R₁ is F; and

R₃ is hydroxy or -OCONH₂.

6. (Cancelled) The compound of claim 1 having the general structure




wherein R₁ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂.

5 7. (Cancelled) The compound of claim 6 wherein R₁ is H; and

R₃ is -OCONH₂.

8. (Cancelled) The compound of claim 1 having the general structure



10 wherein R₁ and R₇ are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R₄ is hydroxy or carbonyl.

9. (Cancelled) The compound of claim 8 wherein R₇ is H.


15

10. (Cancelled) The compound of claim 6 or 9 wherein R₁ is H or F.

11. (Cancelled) A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition 20 comprising a compound selected from the group consisting of



and




wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

5 R₃ is hydroxy or -OCONH₂; and
 R₄ is hydroxy or carbonyl.

12. (Cancelled) The method of claim 11 wherein the composition is administered orally.

10 13. (Cancelled) The method of claim 12 wherein the unit dosage form of the composition comprises about 0.1 mg/kg to about 1 g/kg of said compound.

14. (Cancelled) The method of claim 13 wherein said compound has the
15 general structure



wherein R₁ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R₃ is hydroxy or -OCONH₂.

5


15. (Cancelled) The method of claim 14 wherein R₁ is H; and

R₃ is -OCONH₂.

16. (Cancelled) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of



and




15 wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂; and

R₄ is hydroxy or carbonyl.

17. (Cancelled) The method of claim 16 wherein said compound has the general structure



wherein R₁ is selected from the group consisting of H, halo, haloalkyl
5 and hydroxy; and

R₃ is hydroxy or -OCONH₂.

18. (Cancelled) The method of claim 17 wherein R₁ is H; and
R₃ is -OCONH₂.
10

19. (Cancelled) The method of claim 16 wherein the localized hypoxic condition is caused by cerebral ischemia.


20. (Cancelled) The method of claim 16 wherein the localized hypoxic
15 condition is caused by myocardial ischemia.

21. (Cancelled) The method of claim 16 wherein the composition is administered orally.
20


22. (Cancelled) The method of claim 16 wherein the composition is administered parenterally.
25

23. (Cancelled) The method of claim 22 wherein the unit dosage form of the composition comprises about 1.0 mg/kg to about 1 g/kg of said compound and the composition is administered intravenously.

24. (Cancelled) A pharmaceutical composition comprising a compound selected from the group consisting of




and



wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;
5 R₃ is hydroxy or -OCONH₂; and
R₄ is hydroxy or carbonyl, and a pharmaceutically acceptable carrier.

25. (Cancelled) The composition of claim 24 wherein said compound has
10 the general structure




wherein R₁ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂.

26. (Cancelled) The composition of claim 25 wherein R₁ is selected from the group consisting of halo, haloalkyl and hydroxy.
27. (Cancelled) The composition of claim 25 wherein R₁ is H; and
5 R₃ is -OCONH₂.

28. (Cancelled) The composition of claim 24 wherein said compound has the general structure




10 wherein R₁ and R₇ are independently selected from the group consisting of H, halo, haloalkyl and hydroxy;
and R₃ is hydroxy or -OCONH₂.

29. (Cancelled) The composition of claim 28 wherein R₇ is H.

15
30. (Cancelled) The composition of claim 25, 28 or 29 wherein R₁ is H or F.

- 31.(NEW) A compound of the formula:



wherein: R₂ is halo; and R₃ is hydroxy or -OCONH₂.

- 32.(NEW) The compound of claim 31 wherein R₂ is chloro or fluoro.
- 33.(NEW) The compound of claim 31 wherein R₂ is fluoro.
- 5 34.(NEW) The compound of claim 31 wherein R₃ is hydroxy.
- 35.(NEW) The compound of claim 31 wherein R₃ is -OCONH₂.
- 10 36.(NEW) The compound of claim 34 wherein R₂ is chloro or fluoro.
- 37.(NEW) The compound of claim 34 wherein R₂ is fluoro.
- 38.(NEW) The compound of claim 35 wherein R₂ is chloro or fluoro.
- 15 39.(NEW) The compound of claim 35 wherein R₂ is fluoro.
- 40.(NEW) A composition comprising a compound as described in claim 31, and a pharmaceutically acceptable carrier.
- 20 41. (NEW) A composition comprising a compound as described in claim 39, and a pharmaceutically acceptable carrier.
- 42.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 31.
- 25 43.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising

administering to the patient, an effective amount of a compound as described in claim 31.

- 44.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 39.
5
- 45.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising administering to the patient, an effective amount of a compound as described in claim 39.
10